Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event

Rhea-AI Summary

Microbot Medical (Nasdaq: MBOT) confirms no business disruption in the U.S. or Israel amid current geopolitical events and says employee safety is the top priority. The company says internal operations and its lead manufacturing partner remain fully functional, with sufficient U.S. inventory to support customers.

Following FDA clearance, Microbot began a limited market release of the LIBERTY Endovascular Robotic System in late 2025 and plans a full market release at the SIR conference in April 2026. The company is expanding U.S. commercial infrastructure with new sales hires and a Director of HEOR, and is building additional U.S. stock via a third-party logistics partner.

Positive

• FDA clearance of the LIBERTY system
• Limited market release commenced in late 2025
• Planned full market release at SIR April 2026
• Sufficient U.S. inventory to support current customers
• Expanded U.S. commercial team with new sales hires and HEOR director

Negative

• None.

Key Figures

Share price: $2.48 Daily change: 2.9% 52-week range: $1.25 – $4.67 +5 more

8 metrics

Share price $2.48 Prior close before this news

Daily change 2.9% Price change over last 24 hours

52-week range $1.25 – $4.67 52-week low and high

Market cap $161,850,886 Equity value before this news

Shelf expenses $25,000.00 Total issuance and distribution expenses in S-3/A

SEC fee $404.02 SEC registration fee in S-3/A

CEO option grant 480,000 shares Stock options granted under 2020 Omnibus Plan

Special CEO bonus $140,000 One-time cash award authorized February 18, 2026

Market Reality Check

Price: $2.48 Vol: Volume 1,862,527 vs 20-da...

low vol

$2.48 Last Close

Volume Volume 1,862,527 vs 20-day average 3,127,905 suggests no outsized trading reaction. low

Technical Shares at $2.48 are trading below the 200-day MA of $2.58, despite recent positive news flow.

Peers on Argus

MBOT was up about 2.9%, while only one scanned peer (ZTEK) showed momentum and m...

1 Down

MBOT was up about 2.9%, while only one scanned peer (ZTEK) showed momentum and moved down 6.29%, indicating a stock‑specific reaction rather than a sector‑wide move.

Historical Context

5 past events · Latest: Feb 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Hospital adoption	Positive	+23.9%	Tampa General Hospital becomes first Florida adopter post‑FDA clearance.
Feb 19	Conference visibility	Positive	+2.4%	CEO features on innovation panel showcasing LIBERTY at surgical summit.
Feb 12	Conference highlight	Positive	+4.5%	LIBERTY highlighted at major vascular disease management conference.
Feb 05	Oncology meeting demo	Positive	-6.9%	Showcase and hands‑on demos at Society of Interventional Oncology meeting.
Jan 12	Milestones update	Positive	+1.9%	2025 LIBERTY milestones and 2026 targets, including Q2 2026 full release.

Pattern Detected

Recent LIBERTY commercialization and visibility updates have generally seen positive price alignment, with one notable divergence on a conference‑focused release.

Recent Company History

Over the past few months, MBOT has repeatedly highlighted progress for its LIBERTY® Endovascular Robotic System, including FDA 510(k) clearance, limited market release in late 2025, and a planned full market release at SIR in April 2026. Hospitals such as Tampa General have adopted the system, and LIBERTY has been showcased at multiple conferences. Today’s update on operational stability and uninterrupted U.S. commercialization activity fits into this ongoing commercialization narrative.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-28

The company has an active S-3/A shelf registration filed on 2025-10-28, with Amendment No. 1 mainly addressing effectiveness language and exhibit cross‑references. The filing lists total issuance and distribution expenses of $25,000.00 and an SEC registration fee of $404.02. The shelf was not yet effective as of the provided data, though it has been used in conjunction with two 424B3 filings on 2025-11-19.

Market Pulse Summary

This announcement underscores that MBOT’s U.S. and Israeli operations, including its LIBERTY® Endova...

Analysis

This announcement underscores that MBOT’s U.S. and Israeli operations, including its LIBERTY® Endovascular Robotic System manufacturing and logistics, remain fully functional despite geopolitical tensions. The company highlights recent FDA clearance, a limited market release begun in late 2025, and plans for a full launch at the SIR conference in April 2026. Added U.S. sales hires and inventory build support this trajectory, while an active S-3/A shelf and recent option grants frame capital and governance considerations.

Key Terms

endovascular, peripheral endovascular procedures, fda clearance, health economics and outcomes research (heor), +2 more

6 terms

endovascular medical

"LIBERTY® Endovascular Robotic System, announced today that the Company..."

Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.

peripheral endovascular procedures medical

"robotic system for peripheral endovascular procedures, and it is designed..."

Minimally invasive treatments that repair or open narrowed, blocked or damaged blood vessels outside the heart and brain by threading small tools through the vessel—think of fixing a clogged pipe from the inside using balloons, tiny cutters or scaffolds. Investors care because these procedures drive sales for medical devices, hospital revenue and recurring consumables, and their growth depends on aging populations, reimbursement rules and regulatory approvals that affect company earnings and adoption rates.

fda clearance regulatory

"Following the recent FDA clearance of LIBERTY, the commercial focus..."

FDA clearance is the U.S. Food and Drug Administration’s official permission to market certain medical devices or diagnostic tests after reviewing evidence that they are as safe and effective as similar products already on the market. For investors, it’s like a product passing a required safety inspection — it reduces regulatory uncertainty, speeds commercial rollout, and can directly affect sales prospects, valuation, and partnership opportunities.

health economics and outcomes research (heor) medical

"along with a Director of Health Economics and Outcomes Research (HEOR)..."

Health economics and outcomes research (HEOR) studies how well medical treatments work in the real world and what they cost, combining clinical results, patient experiences, and economic analysis to judge value. For investors, HEOR is like a product report card and price guide: it helps predict whether insurers, hospitals and doctors will adopt and pay for a therapy, influencing sales, pricing power and long-term revenue potential.

logistics partner technical

"through its U.S.-based third-party logistics partner to meet anticipated demand."

A logistics partner is an outside company hired to handle moving, storing and delivering a business’s products—think of them as the moving and storage crew that ensures packages get from factory to customer. For investors, the choice and performance of a logistics partner affect costs, delivery speed, customer satisfaction and a company’s ability to grow or respond to problems, so changes in logistics arrangements can influence profitability and risk.

radiation exposure medical

"aiming to reduce radiation exposure and physical strain."

Radiation exposure is the amount of ionizing energy from sources like X-rays, medical treatments, industrial equipment, or nuclear materials that people, products, or environments receive; think of it like sun exposure but from invisible high-energy rays that can damage cells over time. Investors care because excessive exposure can trigger health risks, regulatory fines, facility shutdowns, cleanup costs and liability claims, all of which can affect a company’s operations, reputation and financial outlook.

AI-generated analysis. Not financial advice.

HINGHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced today that the Company, both in the USA and in Israel, is not experiencing any business disruption as a result of current geopolitical events. The safety and security of the employees remain its top priority. All personnel continue to operate as usual, and both internal operations and the lead manufacturing partner remain fully functional.

Following the recent FDA clearance of LIBERTY, the commercial focus of the Company has been on the U.S. market, managed by its dedicated U.S.-based commercial team headquartered in Hingham, MA. This ensures uninterrupted service, reliable distribution, and continued advancement of the limited market release of the LIBERTY System as planned. The Company maintains sufficient inventory in the U.S. to support current customers and is actively building additional stock through its U.S.-based third-party logistics partner to meet anticipated demand.

In preparation for the full market release of the LIBERTY System at the Society of Interventional Radiology (SIR) annual meeting next month, and amid the growing market interest, the Company continues to strengthen its commercial infrastructure. It recently hired additional sales representatives to expand coverage into new U.S. territories, along with a Director of Health Economics and Outcomes Research (HEOR) to further support and enhance its commercial expansion.

The Company is closely monitoring the situation in the Middle East to ensure the ongoing well-being of its employees and to ensure uninterrupted support for customers, reinforcing its commitment to operational excellence.

LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company commenced the limited market release of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

FAQ

Is Microbot Medical (MBOT) experiencing operational disruptions due to the March 2026 geopolitical event?

No—operations in the U.S. and Israel continue without disruption, according to the company. The company says internal operations and its lead manufacturing partner remain fully functional, and employee safety remains the top priority while the situation is monitored.

What is Microbot Medical's (MBOT) timeline for the full LIBERTY system market release?

The company plans a full market release at the Society of Interventional Radiology conference in April 2026, according to the company. This follows a limited market release that began in late 2025 and aims to deepen market adoption.

Does Microbot Medical (MBOT) have inventory to serve current U.S. customers?

Yes—the company maintains sufficient inventory in the U.S. to support current customers, according to the company. It is also building additional stock through a U.S.-based third-party logistics partner to meet anticipated demand.

How is Microbot Medical (MBOT) strengthening its U.S. commercial infrastructure ahead of SIR 2026?

Microbot has hired additional sales representatives and a Director of HEOR to expand U.S. coverage and support commercial expansion, according to the company. These hires aim to increase territory coverage and strengthen health economics capabilities.

What is LIBERTY and how does Microbot Medical (MBOT) describe its clinical purpose?

LIBERTY is an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, according to the company. It is designed for precise vascular navigation while aiming to reduce radiation exposure and operator physical strain.